I don’t know who needs to hear this (as you’re blocked) but smaller population = more difficult to achieve statistically meaningful/significant outcomes.
These are rare genetic diseases and thus large scale recruitment is a challenge. This does not detract from the results here imo.
- Forums
- ASX - By Stock
- Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
I don’t know who needs to hear this (as you’re blocked) but...
-
- There are more pages in this discussion • 126 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.81 |
Change
0.060(0.44%) |
Mkt cap ! $1.765B |
Open | High | Low | Value | Volume |
$13.85 | $14.08 | $13.46 | $6.963M | 507.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3724 | $13.69 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.84 | 2087 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3724 | 13.690 |
1 | 2087 | 13.670 |
2 | 6767 | 13.650 |
1 | 1752 | 13.630 |
1 | 2087 | 13.620 |
Price($) | Vol. | No. |
---|---|---|
13.840 | 2087 | 1 |
13.870 | 2087 | 1 |
13.890 | 2087 | 1 |
13.920 | 2087 | 1 |
13.980 | 500 | 1 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |